Platelet-Endothelial Cell-Cell Interactions at the Onset of Atherosclerosis: Mechanisms and Implications

Francesco Vieceli Dalla Sega1, Francesca Fortini1, Alessia Ascierto2

  • 1Maria Cecilia Hospital, GVM Care & Research, Cotignola, Italy.

Thrombosis and Haemostasis
|November 25, 2025
PubMed

Platelets are primarily known for their roles in hemostasis and thrombosis; however, accumulating evidence highlights their significant contribution to endothelial dysfunction and the development of atherosclerosis. Upon adhering to the endothelium, platelets engage in reciprocal activation through a variety of membrane receptors and adhesion molecules, initiating inflammatory and immune responses that drive early atherogenic processes. Several studies have shown that platelet receptors traditionally associated with hemostasis also mediate adhesion to endothelial cells. In addition, recent research has uncovered novel molecular players and mechanisms involved in platelet tethering to the endothelium. This review explores the mechanisms underlying endothelial-platelet interactions during the early stages of atherosclerosis. We examine how platelet adhesion to endothelial cells contributes to the formation of atherosclerotic plaques and discuss potential therapeutic strategies aimed at disrupting these pro-atherogenic interactions. In particular, we discuss emerging anti-platelet agents that selectively target receptors involved in platelet-endothelial cell interactions, offering promising translational approaches to prevent or slow the onset of atherosclerosis.

Related Concept Videos

Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
835
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
348
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
8.6K
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
290
Inflammation01:38

Inflammation

Overview
61.5K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.1K